Related Experiment Videos
Transient effect of aspirin on collagen-induced platelet accumulation
Insights
Aspirin
Area of Science:
- Biomedical Engineering
- Hematology
- Cardiovascular Research
Background:
- Collagen exposure triggers platelet aggregation and thrombus formation.
- Understanding platelet activation pathways is crucial for antithrombotic therapies.
Purpose of the Study:
- To investigate the efficacy of aspirin in preventing collagen-induced thrombus formation.
- To compare aspirin's effects with prostacyclin and anti-von Willebrand factor antibody.
Main Methods:
- Collagen fibers (catgut) were placed in polyethylene tubing and perfused with heparinized blood.
- Perfusion pressure monitored to detect platelet accumulation and occlusion.
- Varying concentrations of aspirin were tested, alongside prostacyclin and anti-von Willebrand factor antibody.
Main Results:
- Prostacyclin and anti-von Willebrand factor antibody completely inhibited thrombus formation.
- Aspirin delayed thrombus onset in a dose-dependent manner.
- At high concentrations, aspirin did not prevent thrombus growth, which occurred at the same rate as controls.
Conclusions:
- Aspirin's ability to prevent collagen-induced thrombus formation is limited.
- Findings suggest that aspirin's clinical antithrombotic benefit as a platelet release inhibitor may be questionable.
Abstract:
A piece of collagen fiber (catgut) was placed into polyethylene tubing and perfused with heparinized blood. The perfusion pressure was monitored, and the pressure rise indicated platelet accumulation around collagen leading to occlusion of the tubing. Continuous slow infusion of prostacyclin into the blood or monoclonal antibody against von Willebrand factor completely prevented thrombus formation. Aspirinization of blood (0.1-2 mM) resulted in a concentration-dependent delay of the onset of thrombus growth, but even at the highest aspirin concentration, the thrombus did finally grow and at the same rate as that of the nonaspirinated control platelets. These findings question the clinical anti-thrombotic benefit of aspirin as platelet release inhibitor.